SKYRIZI is indicated for the treatment of adult patients with moderately to severely active Crohnʼs disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.1
ABBVIE CARE FOR SKYRIZI CD AIMS TO HELP YOUR PATIENTS ENGAGE WITH AND NAVIGATE THEIR SKYRIZI TREATMENT PLAN
Resources for your patients prescribed SKYRIZI, designed with input from patients living with Crohnʼs disease (CD) and healthcare professionals like you.
Supporting your patients at each step of the treatment journey
While every patient is different, providing the right support at the right time can help their treatment plan feel more manageable. Whether this is your patientʼs first time using an injectable medication or not, AbbVie Care offers a range of resources that can help patients understand SKYRIZI, their treatment plan, and how to use the on-body injector (OBI) device correctly.
Induction
Transition
Maintenance
Induction
Transition
Maintenance
Induction
Materials in this phase aim to leverage the patientʼs time in the infusion chair and help them understand their treatment plan. These materials include:
- AbbVie Care for SKYRIZI Welcome Pack*
- Starting SKYRIZI booklet with appointment notes and symptom tracking activities sheet
- myAbbVieCare Patient Portal website* [Affiliate to remove if not applicable]
- Support from a dedicated Care Coach
[Affiliate to remove if not applicable] - Patient Information leaflet included in the medication packaging
*Patients must be enrolled in AbbVie Care for access to these specific materials.
Transition
Materials in this phase aim to help your patients transition from their infusion doses to self-injection with their OBI at home. These materials will introduce your patients to the OBI and help them understand how it works before they move into the maintenance phase. These materials include:
- Starting SKYRIZI booklet with pre-injection checklist
- myAbbVieCare Patient Portal website* [Affiliate to remove if not applicable]
- Support from a dedicated Care Coach
[Affiliate to remove if not applicable] - The interactive OBI 360° experience
- Moving From Infusions to the OBI video
- Training with the OBI Demonstration kit
- Patient Information leaflet included in the medication packaging
*Patients must be enrolled in AbbVie Care for access to these specific materials.
Maintenance
Materials in this phase aim to build your patientsʼ confidence with their OBI device. They intend to support patients during their at-home self-injection treatment, including troubleshooting tips and contact information. These materials include:
- Starting SKYRIZI booklet with goal-setting activity sheets and tips for sustaining long-term wellness*
- myAbbVieCare Patient Portal website* [Affiliate to remove if not applicable]
- Support from a dedicated Care Coach
[Affiliate to remove if not applicable] - Welcome to the Maintenance Phase quick reference sheet
- Step-by-step OBI Injection video
- Patient Information leaflet included in the medication packaging
*Patients must be enrolled in AbbVie Care for access to these specific materials.
About AbbVie Care and how to enroll your patients
AbbVie Care is a personalized patient support program that offers additional information and resources for your patients at each step of their treatment plan. Patients enrolled in Abbvie Care have access to:
- Additional educational training materials
across their induction, transition, and maintenance phases - A team of Care Coaches [Affiliates to localise based on market availability] that they can contact if they have any questions about their treatment and treatment plan
- The myAbbVieCare Patient Portal, which allows patients to follow along with their treatment plan, record doses, manage their appointments, along with disease educational content
Encourage your SKYRIZI CD patients to enroll in AbbVie Care so they can access these additional resources
Contact phone number
Contact email?
Mailing address?
Contact website
Scan this QR code for lorem ipsum dolor
Find out more about SKYRIZI
Affiliate to add link.
Indication1
SKYRIZI is indicated for the treatment of adult patients with moderately to severely active Crohnʼs disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.
Important Safety Information1
Affiliate to insert local ISI.
Reference: 1. SKYRIZI [Summary of Product Characteristics]. Ludwigshafen, Germany: AbbVie Deutschland GmbH & Co; January 2024.
ALL-SKZG-220066 February 2024